{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T01:41:01Z","timestamp":1778031661029,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-78539-4","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:22:12Z","timestamp":1735852932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib"],"prefix":"10.1038","volume":"15","author":[{"given":"Hideko","family":"Ohama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Hirooka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Kariyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Takaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ei","family":"Itobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Fukunishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Tajiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikara","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Kakizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritomo","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomitsu","family":"Matono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekatsu","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Yata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fujimasa","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Nouso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asahiro","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akemi","family":"Tsutsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Itokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taeang","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michitaka","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Kaibori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Hiasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"78539_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"78539_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378\u2013390. https:\/\/doi.org\/10.1056\/NEJMoa0708857 (2008).","journal-title":"N. Engl. J. Med."},{"key":"78539_CR3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/s0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163\u20131173. https:\/\/doi.org\/10.1016\/s0140-6736(18)30207-1 (2018).","journal-title":"Lancet"},{"key":"78539_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/s0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56\u201366. https:\/\/doi.org\/10.1016\/s0140-6736(16)32453-9 (2017).","journal-title":"Lancet"},{"key":"78539_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/s1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu, A. X. et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 282\u2013296. https:\/\/doi.org\/10.1016\/s1470-2045(18)30937-9 (2019).","journal-title":"Lancet Oncol."},{"key":"78539_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1717002 (2018).","journal-title":"N. Engl. J. Med."},{"key":"78539_CR7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745 (2020).","journal-title":"N. Engl. J. Med."},{"key":"78539_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","volume":"40","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa, G. K. et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J. Clin. Oncol. 40, 379\u2013379. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.379 (2022).","journal-title":"J. Clin. Oncol."},{"key":"78539_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol. 76, 681\u2013693. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018 (2022).","journal-title":"J. Hepatol."},{"key":"78539_CR10","doi-asserted-by":"publisher","DOI":"10.1159\/000531316","author":"A Hiraoka","year":"2023","unstructured":"Hiraoka, A. et al. Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma-clinical results show importance of hepatic reserve function. Oncology https:\/\/doi.org\/10.1159\/000531316 (2023).","journal-title":"Oncology"},{"key":"78539_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000506293","volume":"98","author":"A Hiraoka","year":"2020","unstructured":"Hiraoka, A. et al. Nutritional index as prognostic indicator in patients receiving lenvatinib treatment for unresectable hepatocellular carcinoma. Oncology 98, 295\u2013302. https:\/\/doi.org\/10.1159\/000506293 (2020).","journal-title":"Oncology"},{"key":"78539_CR12","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/liv.14405","volume":"40","author":"T Tada","year":"2020","unstructured":"Tada, T. et al. Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Liver Int. 40, 968\u2013976. https:\/\/doi.org\/10.1111\/liv.14405 (2020).","journal-title":"Liver Int."},{"key":"78539_CR13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/meg.0000000000002398","volume":"34","author":"T Tada","year":"2022","unstructured":"Tada, T. et al. Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. Eur. J. Gastroenterol. Hepatol. 34, 857\u2013864. https:\/\/doi.org\/10.1097\/meg.0000000000002398 (2022).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"78539_CR14","doi-asserted-by":"publisher","first-page":"6980","DOI":"10.1002\/cam4.5495","volume":"12","author":"T Tada","year":"2023","unstructured":"Tada, T. et al. New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study. Cancer Med. 12, 6980\u20136993. https:\/\/doi.org\/10.1002\/cam4.5495 (2023).","journal-title":"Cancer Med."},{"key":"78539_CR15","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1111\/jgh.15336","volume":"36","author":"A Hiraoka","year":"2021","unstructured":"Hiraoka, A. et al. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. J. Gastroenterol. Hepatol. 36, 1812\u20131819. https:\/\/doi.org\/10.1111\/jgh.15336 (2021).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"78539_CR16","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1002\/cam4.2241","volume":"8","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka, A. et al. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-multicenter analysis. Cancer Med. 8, 3719\u20133728. https:\/\/doi.org\/10.1002\/cam4.2241 (2019).","journal-title":"Cancer Med."},{"key":"78539_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/ajcn\/82.4.777","volume":"82","author":"O Bouillanne","year":"2005","unstructured":"Bouillanne, O. et al. Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am. J. Clin. Nutr. 82, 777\u2013783. https:\/\/doi.org\/10.1093\/ajcn\/82.4.777 (2005).","journal-title":"Am. J. Clin. Nutr."},{"key":"78539_CR18","doi-asserted-by":"publisher","first-page":"9038","DOI":"10.1038\/s41598-021-88254-z","volume":"11","author":"H Kanno","year":"2021","unstructured":"Kanno, H. et al. Geriatric nutritional risk index predicts prognosis in hepatocellular carcinoma after hepatectomy: a propensity score matching analysis. Sci. Rep. 11, 9038. https:\/\/doi.org\/10.1038\/s41598-021-88254-z (2021).","journal-title":"Sci. Rep."},{"key":"78539_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13934","author":"A Hiraoka","year":"2023","unstructured":"Hiraoka, A. et al. Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Hepatol. Res. https:\/\/doi.org\/10.1111\/hepr.13934 (2023).","journal-title":"Hepatol. Res."},{"key":"78539_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach, J. K. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67, 358\u2013380. https:\/\/doi.org\/10.1002\/hep.29086 (2018).","journal-title":"Hepatology"},{"key":"78539_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs.1800600817","volume":"60","author":"RN Pugh","year":"1973","unstructured":"Pugh, R. N., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C. & Williams, R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60, 646\u2013649. https:\/\/doi.org\/10.1002\/bjs.1800600817 (1973).","journal-title":"Br. J. Surg."},{"key":"78539_CR22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/jco.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson, P. J. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J. Clin. Oncol. 33, 550\u2013558. https:\/\/doi.org\/10.1200\/jco.2014.57.9151 (2015).","journal-title":"J. Clin. Oncol."},{"key":"78539_CR23","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/jgh.13250","volume":"31","author":"A Hiraoka","year":"2016","unstructured":"Hiraoka, A. et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 31, 1031\u20131036. https:\/\/doi.org\/10.1111\/jgh.13250 (2016).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"78539_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000479984","volume":"6","author":"A Hiraoka","year":"2017","unstructured":"Hiraoka, A. et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer 6, 325\u2013336. https:\/\/doi.org\/10.1159\/000479984 (2017).","journal-title":"Liver Cancer"},{"key":"78539_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026 (2009).","journal-title":"Eur. J. Cancer"},{"key":"78539_CR26","unstructured":"US Department of Health and Human Services, National Institutes of Health & Institute., N. C. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50, https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50."},{"key":"78539_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092091","author":"M Kaibori","year":"2022","unstructured":"Kaibori, M. et al. Comparison of the new neo-glasgow prognostic score based on the albumin-bilirubin grade with currently used nutritional indices for prognostic prediction following surgical resection of hepatocellular carcinoma: A multicenter retrospective study in Japan. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers14092091 (2022).","journal-title":"Cancers (Basel)"},{"key":"78539_CR28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 48, 452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244 (2013).","journal-title":"Bone Marrow Transplant."},{"key":"78539_CR29","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/1759-7714.13909","volume":"12","author":"K Sonehara","year":"2021","unstructured":"Sonehara, K. et al. Prognostic value of the geriatric nutritional risk index among patients with previously treated advanced non-small cell lung cancer who subsequently underwent immunotherapy. Thorac. Cancer 12, 1366\u20131372. https:\/\/doi.org\/10.1111\/1759-7714.13909 (2021).","journal-title":"Thorac. Cancer"},{"key":"78539_CR30","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1186\/s12935-020-01628-7","volume":"20","author":"H Xie","year":"2020","unstructured":"Xie, H., Tang, S., Wei, L. & Gan, J. Geriatric nutritional risk index as a predictor of complications and long-term outcomes in patients with gastrointestinal malignancy: a systematic review and meta-analysis. Cancer Cell Int. 20, 530. https:\/\/doi.org\/10.1186\/s12935-020-01628-7 (2020).","journal-title":"Cancer Cell Int."},{"key":"78539_CR31","doi-asserted-by":"publisher","first-page":"10744","DOI":"10.1038\/s41598-020-67285-y","volume":"10","author":"M Sasaki","year":"2020","unstructured":"Sasaki, M. et al. The Geriatric Nutritional Risk Index predicts postoperative complications and prognosis in elderly patients with colorectal cancer after curative surgery. Sci. Rep. 10, 10744. https:\/\/doi.org\/10.1038\/s41598-020-67285-y (2020).","journal-title":"Sci. Rep."},{"key":"78539_CR32","doi-asserted-by":"publisher","first-page":"12561","DOI":"10.1038\/s41598-018-30906-8","volume":"8","author":"L Li","year":"2018","unstructured":"Li, L. et al. Geriatric nutritional risk index predicts prognosis after hepatectomy in elderly patients with hepatitis B virus-related hepatocellular carcinoma. Sci. Rep. 8, 12561. https:\/\/doi.org\/10.1038\/s41598-018-30906-8 (2018).","journal-title":"Sci. Rep."},{"key":"78539_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000032322","volume":"101","author":"Y Si","year":"2022","unstructured":"Si, Y., Xu, P., Xu, A., Wang, P. & Zhao, K. Geriatric nutritional risk index as a prognostic factor in patients with hepatocellular carcinoma following transarterial chemoembolization: A retrospective study. Medicine (Baltimore) 101, e32322. https:\/\/doi.org\/10.1097\/md.0000000000032322 (2022).","journal-title":"Medicine (Baltimore)"},{"key":"78539_CR34","doi-asserted-by":"publisher","first-page":"865","DOI":"10.21873\/invivo.12775","volume":"36","author":"A Kinoshita","year":"2022","unstructured":"Kinoshita, A. et al. The geriatric nutritional risk index predicts tolerability of lenvatinib in patients with hepatocellular carcinoma. In Vivo 36, 865\u2013873. https:\/\/doi.org\/10.21873\/invivo.12775 (2022).","journal-title":"In Vivo"},{"key":"78539_CR35","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/jso.21857","volume":"103","author":"M Ishizuka","year":"2011","unstructured":"Ishizuka, M. et al. Usefulness of a modified inflammation-based prognostic system for predicting postoperative mortality of patients undergoing surgery for primary hepatocellular carcinoma. J. Surg. Oncol. 103, 801\u2013806. https:\/\/doi.org\/10.1002\/jso.21857 (2011).","journal-title":"J. Surg. Oncol."},{"key":"78539_CR36","first-page":"619","volume":"32","author":"M Morimoto","year":"2012","unstructured":"Morimoto, M. et al. Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment. Anticancer Res. 32, 619\u2013623 (2012).","journal-title":"Anticancer Res."},{"key":"78539_CR37","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.ejso.2008.01.016","volume":"34","author":"G Morris-Stiff","year":"2008","unstructured":"Morris-Stiff, G., Gomez, D. & Prasad, K. R. C-reactive protein in liver cancer surgery. Eur. J. Surg. Oncol. 34, 727\u2013729. https:\/\/doi.org\/10.1016\/j.ejso.2008.01.016 (2008).","journal-title":"Eur. J. Surg. Oncol."},{"key":"78539_CR38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00535-016-1263-4","volume":"52","author":"K Ikeda","year":"2017","unstructured":"Ikeda, K. et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J. Gastroenterol. 52, 512\u2013519. https:\/\/doi.org\/10.1007\/s00535-016-1263-4 (2017).","journal-title":"J. Gastroenterol."},{"key":"78539_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231828","volume":"15","author":"S Kirino","year":"2020","unstructured":"Kirino, S. et al. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS One 15, e0231828. https:\/\/doi.org\/10.1371\/journal.pone.0231828 (2020).","journal-title":"PLoS One"},{"key":"78539_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/cam4.1909","volume":"8","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka, A. et al. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. Cancer Med. 8, 137\u2013146. https:\/\/doi.org\/10.1002\/cam4.1909 (2019).","journal-title":"Cancer Med."},{"key":"78539_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112608","author":"K Tsuchiya","year":"2021","unstructured":"Tsuchiya, K. et al. The real-world data in Japanese patients with unresectable hepatocellular carcinoma treated with lenvatinib from a nationwide multicenter study. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13112608 (2021).","journal-title":"Cancers (Basel)"},{"key":"78539_CR42","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/s0899-9007(98)00171-3","volume":"15","author":"B Vellas","year":"1999","unstructured":"Vellas, B. et al. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. Nutrition 15, 116\u2013122. https:\/\/doi.org\/10.1016\/s0899-9007(98)00171-3 (1999).","journal-title":"Nutrition"},{"key":"78539_CR43","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clnesp.2021.08.015","volume":"45","author":"AW Gomes-Neto","year":"2021","unstructured":"Gomes-Neto, A. W. et al. Malnutrition universal screening tool and patient-generated subjective global assessment short form and their predictive validity in hospitalized patients. Clin. Nutr. ESPEN 45, 252\u2013261. https:\/\/doi.org\/10.1016\/j.clnesp.2021.08.015 (2021).","journal-title":"Clin. Nutr. ESPEN"},{"key":"78539_CR44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/s0261-5614(02)00214-5","volume":"22","author":"J Kondrup","year":"2003","unstructured":"Kondrup, J., Rasmussen, H. H., Hamberg, O. & Stanga, Z. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin. Nutr. 22, 321\u2013336. https:\/\/doi.org\/10.1016\/s0261-5614(02)00214-5 (2003).","journal-title":"Clin. Nutr."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78539-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78539-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78539-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T14:04:21Z","timestamp":1735913061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78539-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["78539"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-78539-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3462561\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"18 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The entire study protocol was approved by the Institutional Ethics Committee of Ehime Prefectural Central Hospital (No.2022-46). After receiving official approval, this study was conducted as a retrospective analysis of database records based on the Guidelines for Clinical Research issued by the Ministry of Health and Welfare of Japan. All procedures were done in accordance with the declaration of Helsinki. The data were made anonymous before analysis to protect patient privacy. Written informed consent was obtained from all patients before treatment and this study received ethical approval for use of an opt-out methodology based on low risk to the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of ethics"}},{"value":"Atsushi Hiraoka, MD, PhD: lecture fees; AstraZeneca, Bayer, and Eli Lilly. Takashi Kumada, MD, PhD: lecture fees; Eisai. Toshifumi Tada, MD, PhD: Abbvie and Eisai. Takeshi Hatanaka, MD, PhD: Eisai. None of the other authors have potential conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}